SCHEMBL810264

SCHEMBL810264

Nc1cc(OCc2cc(F)ccc2Cl)ccc1Sc1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.43
SLC6A4 P31645 6/20 0.43
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 2/20 0.40
CACNA1C Q13936 1/20 0.39
AGBL2 Q5U5Z8 1/20 0.37
SLC6A3 Q01959 1/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAOB P27338 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.34
PDE7A Q13946 1/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811162 0.88 CACNA1C (0.51) SLC6A2SLC6A4KDM4EALDH1A1MAPT
SCHEMBL810574 0.82 MAOB (0.49) SLC6A2SLC6A4KDM4EALDH1A1MAPT
SCHEMBL810727 0.82 PDE7A (0.49) KDM4EALDH1A1MAPTAGBL2LMNA
SCHEMBL811689 0.79 MAOB (0.54) MAOB
SCHEMBL5087355 0.79 CACNA1C (0.48) SLC6A4CACNA1CMAOBALOX5APFEN1
SCHEMBL811060 0.78 PARP10 (0.48) SLC6A2SLC6A4KDM4EALDH1A1MAPT
SCHEMBL5069013 0.78 KDM4E (0.45) SLC6A2SLC6A4KDM4EALDH1A1MAPT
SCHEMBL2969952 0.77 KDM4E (0.47) SLC6A2SLC6A4KDM4EALDH1A1MAPT
SCHEMBL810856 0.75 MAOB (0.44) SLC6A2SLC6A4KDM4EALDH1A1MAPT
SCHEMBL810986 0.75 PIM1 (0.52) SLC6A2SLC6A4ALDH1A1SLC6A3MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
CN-101443334-A Anti-viral compounds ABBOTT LAB (US) 2009-05-27 CN disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SLC6A2 4033/4885SLC6A4 4037/4885KDM4E 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.